Sector | Information Technology | Compare with Sector peers |
Industry | IT - Software | Compare with Industry peers |
Website | http://www.kashyaptele-medicines.com | |
Market Cap | 10.26 Cr. | |
Enterprise Value(EV) | 10.26 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 0.00 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-12 |
Industry PE | 29.57 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 0.14 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 15.27 | Calculated using Price: 2.15 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 4.77 Cr. | 47,722,000 Shares |
FaceValue | 1 | |
About Kashyap Tele-Medicines Ltd. | ||
Kashyap Tele-Medicines was incorporated on February 20, 1995 and is based in Ahmedabad. It is one of the leading internet service providers (ISPs) in Gujarat. The company provides value-enhanced technical solutions and professional expertise through a host of services like customized internet and extranet solutions, software application development and networking solutions and services. It specializes in developing custom-made software solutions and services in customer relation management and supply chain management. Services include web-enabled services, data conversion, import and export; end-to-end networking solutions to the end user; and cutting-edge software solutions in mainframe client server and internet environments. The company is mainly engaged in corporate loans, advances & dealing in shares & securities, providing internet services & other allied services. |
1 Day |
|
|
1 Week |
|
+6.97% |
1 Month |
|
+1.90% |
3 Month |
|
+43.33% |
6 Month |
|
+9.69% |
1 Year |
|
+31.90% |
2 Year |
|
+216.18% |
5 Year |
|
+216.18% |
10 Year |
|
+726.92% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 1.44 | 1.14 | 1.73 | 1.76 | 0.98 | 0.56 | 0.46 | -112.88 | 0.46 | |
Return on Capital Employed (%) | 1.37 | 1.34 | 2.03 | 2.16 | 1.35 | 0.63 | 0.63 | -112.94 | 0.64 | |
Return on Assets (%) | 1.36 | 1.08 | 1.62 | 1.7 | 0.97 | 0.56 | 0.46 | -112.02 | 0.46 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | |
Non Curr. Liab. | |||||||||||
Curr. Liab. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Minority Int. | |||||||||||
Equity & Liab. | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | |
Non Curr. Assets | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | |
Curr. Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Other Income | |||||||||||
Total Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Total Expenditure | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
PBIDT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Interest | |||||||||||
Depreciation | |||||||||||
Taxation | 0 | 0 | 0 | 0 | |||||||
Exceptional Items | -2 | ||||||||||
PAT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 | |||
Adjusted EPS | 0 | 0 | 0 | 0 | 0 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Cash Fr. Inv. | |||||||||||
Cash Fr. Finan. | |||||||||||
Net Change | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sat, 20 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: JYOTI SAHU Designation: Company Secretary and Compliance Officer EmailId: investor.relations@kashyaptele-medicines.com Name of the Chief Financial Officer: Raghav Agrawal Designation: Director and Chief Financial Officer EmailId: investor.relations@kashyaptele-medicines.com Date: 20/04/2024 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
|||||||||||||||||||||
Sat, 13 Apr 2024
Compliances-Under Regulation 40(9) And Regulation 40(10) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Compliances-Under Regulations 40(9) and Regulations 40(10) of the SEBI (LODR) Regulations 2015 |
|||||||||||||||||||||
Mon, 08 Apr 2024
Compliances- Certificate Under Regulation 7(3) Of The SEBI(LODR) Regulations 2015 For The Period Ended 31St March 2024 Certificate under Regulations 7(3) of the SEBI(LODR) Regulations 2015 |
Wed, 24 Apr 2024 |
High Delivery Percentage |
Opening at Low |
Opening at Low for 3 days |
Closing Above Previous High |
Opening at Low for 2 Days |